A clinical-stage biopharmaceutical company focused on identifying.

Kinneret Savitsky, CEO of BioLineRx.. BioLineRx announces in-licensing of BL-1110 substance for treatment of neuropathic pain BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on identifying, developing and in-licensing promising therapeutic applicants, today it provides in-certified BL-1110 announced, a novel substance for the treating neuropathic pain. BL-1110 could be developed for the treating scleroderma also, an autoimmune disease seen as a a hardening and tightening of your skin and connective cells. The compound, which have been previously developed within BioLineRx's Early Advancement Program beneath the true name EDP-34, was in-licensed from the University of Colorado. Neuropathic pain is due to diseases or harm affecting the nervous program, and will not respond well to regular painkillers usually.Furthermore, Micromet will end up being reimbursed because of its R&D expenses. Related StoriesCMC Biologics, River Eyesight sign manufacturing contract for Teprotumumab to take care of Grave's OrbitopathyMorphoSys, Immatics partner to build up novel antibody-based therapies against multiple proprietary malignancy antigensJanssen signs license contract with Alligator Bioscience for immuno-oncology antibody’BiTE antibodies represent a promising method of cancer tumor therapy,’ said Dr. Karl Ziegelbauer, Head Therapeutic Study Oncology of Bayer Schering Pharma AG. ‘We are happy with the improvement of the program because the signing of the contract in January of the calendar year.